Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.
Illumina Company Profile
President & CEO: Francis deSouza
Ticker symbol: ILMN
Headquarters: San Diego, CA
Illumina employees: 5,500+ globally
Revenues: $2.4 Billion USD in 2016
Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel
Illumina Pushes Back Against Icahn's Proposed Board Nominees
The company issued a defense of its management and board while striking back against Carl Icahn’s recent comments and moves to start a proxy fight for the firm's board of directors.
New Products Posted to GenomeWeb: Illumina, NeoGenomics, Bionano Laboratories
New products and services posted to GenomeWeb for the week of March 13, 2023.
ACMG: Rare Disease Patients in Poor Countries See Benefit from Clinical Whole-Genome Sequencing
Patients in Illumina's global iHope philanthropic clinical WGS program saw changes in their management regardless of whether they lived in wealthy or poor countries.
At ACMG, GUARDIAN Newborn Sequencing Study Reports High Uptake Rate
The researchers have already identified babies with G6PD deficiency who would have been missed by standard newborn screening.
Illumina Shares Soar as Billionaire Investor Seeks Board Seats to End Grail Takeover 'Insanity'
Activist investor Carl Icahn sent a letter to Illumina shareholders outlining plans to take control of three board seats with the goal of promptly divesting Grail.